[SGEN's naked anti-CD30 Mab is in the clinic]
Seattle Genetics Reports Progress in its SGN-35 Program
Monday August 11, 9:04 am ET
BOTHELL, Wash.--(BUSINESS WIRE)--Aug. 11, 2003--Seattle Genetics, Inc. (Nasdaq:SGEN - News) announced today the publication of preclinical data on its SGN-35 product candidate, an antibody-drug conjugate (ADC), in the August 15, 2003 issue of Blood, the Journal of the American Society of Hematology.
The research illustrates that SGN-35 is highly efficacious at low doses and is capable of selectively targeting CD30-positive malignancies in models of Hodgkin's disease and certain types of non-Hodgkin's lymphoma.
"SGN-35 has yielded impressive preclinical data, demonstrating potent antitumor activity at doses as low as 0.5 milligram per kilogram," commented Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. "Based on these findings, we are developing SGN-35 for future clinical evaluation in patients with hematologic malignancies. In addition, we are investigating SGN-35 as a potential treatment for immunologic diseases."
SGN-35 (cAC10-vcMMAE) is an ADC composed of an anti-CD30 monoclonal antibody linked to a derivative of the highly potent, cell-killing drug Auristatin E using Seattle Genetics' proprietary, next-generation ADC technology. The synthetic drug-linker system is designed for stability while in the bloodstream, but allows for active drug release under conditions present within target tumor cells. This targeted approach to cancer therapy is intended to maximize the antitumor activity of SGN-35 while reducing the toxic side effects associated with traditional chemotherapy.
In addition to SGN-35, Seattle Genetics is actively evaluating other tumor-reactive monoclonal antibodies for use with its ADC technology. By arming monoclonal antibodies with potent drug payloads, Seattle Genetics can further exploit their potential as therapeutics. The company licenses its ADC technology to other companies developing targeted therapies for cancer and immunologic disease. |
